CEO Manuel Aivado appointed principal financial officer after CFO Richard Wanstall resigns

Rein Therapeutics, Inc.

CFO Richard J. Wanstall resigned effective May 6, 2022.
On June 5, 2022, CEO Manuel Aivado appointed as principal financial and accounting officer.
Dr. Aivado has served as President and CEO since September 2018; no arrangement or family relationships.
No transactions disclosed between Aivado and company per Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard J. Wanstall

Chief Financial Officer

RNTX · Rein Therapeutics, Inc.

Effective: 2022-05-06
Successor: Manuel Aivado
Filed: June 7, 2022, 7:59 PM ET

Richard J. Wanstall, the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, notified the Company of his resignation, effective May 6, 2022.

Appointed

Manuel Aivado

principal financial officer and principal accounting officer

RNTX · Rein Therapeutics, Inc.

Effective: 2022-06-05
Filed: June 7, 2022, 7:59 PM ET

On June 5, 2022, the Board of Directors of the Company appointed Manuel Aivado, M.D., Ph.D., the Company’s President and Chief Executive Officer to serve as the Company’s principal financial officer and principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Richard J. Wanstall resigned as Chief Financial Officer at Rein Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Richard J. Wanstall, the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, notified the Company of his resignation, effective May 6, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Manuel Aivado was appointed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..

Action: appointed
Role: principal financial officer and principal accounting officer

Exact text from the filing

On June 5, 2022, the Board of Directors of the Company appointed Manuel Aivado, M.D., Ph.D., the Company’s President and Chief Executive Officer to serve as the Company’s principal financial officer and principal accounting officer.

View on SEC.gov

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-168878

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.